Preliminary economic results highlighted for the second quarter of 2020:
Dr. Phillip Chan, MD, PhD, CEO of CytoSorbents said: “CytoSorb sales are higher at the time of a quarter of 2020 to succeed in some other quarterly record, with the strength of strong underlying activity in extensive care and applicable sales with COVID-1nine, that more than offset the minimization of average elective surgeries ordered through hospitals around the world. We have treated more than 1,200 COVID-1 patients in nine countries today. In India, third behind the United States and Brazil for The Diversity of COVID-1nine Cases, our wife Biocon recently announced that CytoSorb has now obtained approval from the Indian Comptroller General for Drugs to consider COVID-1nine patients in some cases. Cytokine storm therapy. This, together with our expanded European sales team, positions us well for the expansion of CytoSorb sales for COVID-1nine and other basic programs such as sepsis, m inactive surgery and liver disease. “